07.21.14
Headquarters: Osaka, Japan
twitter.com/TakedaPharmaDe
www.takeda.com
Top Selling Drugs
In late June, Takeda Pharmaceuticals held its 13th ordinary general meeting of shareholders, and there was a bit of tension there. The company appointed Christophe Weber, a veteran of GSK who is French, as the company’s president and COO, with Yasuchika Hasegawa remaining Chairman and CEO.
As news magazines reported,this was the first time a foreigner had been appointed as a senior executive at the venerable Japanese company. Although the company’s shareholders reportedly voted for Mr. Weber by a large margin, one group of shareholders questioned his appointment and Takeda’s globalization strategy, which has included acquisitions of drugmakers like Nycomed of Switzerland and Millennium Pharmaceuticals of the United States.
In addition, media reported that over 100 members of the Takeda family and former executives signed a letter of protest, reportedly based on fear that he might approve Takeda’s sale to a foreign company.
Chairman reaffirms the need for growth and diversity
The company’s chairman Hasegawa addressed criticism of the Millenium and Nycomed acquisitions at the meeting, before the live Q&A.
“Takeda’s presently decreasing profit is not the effect of these acquisitions, but rather due to structural changes that have progressed rapidly, particularly in Japan and the U.S., such as decreasing sales due to generic drug penetration. Following the patent expiry of Takeda’s four blockbusters that had previously driven our performance, as well as decreasing profitability due to the decreasing ratio of inhouse products.
Post-Blockbuster Era Challenges
I’d like to illustrate this through the example of Actos, one of the largest factors in our decreasing profits. Global sales of Actos decreased from 387.9 billion yen in fiscal year 2010 to 36.6 billion yen in 2013 following expiration of its patent protection.The acquisitions were countermeasures designed to assure and recover our growth. With Millennium, Takeda gained access to a strong oncology franchise and strengthened our presence in the U.S., the largest market in the world.
With the Nycomed acquisition, Takeda gained attractive positioning in locations where we were not previously, thus expanding our global footprint to areas from which we can now launch products that we developed ourselves.
Millennium is an important subsidiary in charge of R&D in oncology. Sales in the U.S. for the multiple myeloma drug Velcade were 95 billion yen in 2013, 30% up from the previous year, and we recovered almost 35 billion yen in royalties. Entyvio was approved in the U.S. and Europe and has been launched and has the potential to generate blockbuster sales. MLN9708 is in the final stages of development as Velcade’s successor in our multiple mueloma franchise, and is now in Phase III development…”
Takeda’s leadership seems committed to looking within and without its boundaries to strengthen its innovation.
twitter.com/TakedaPharmaDe
www.takeda.com
Headcount: | 31,225 | |
Year Established: | 1781 | |
Pharma Revenues: | $16,453 | 9% |
Net Income: | $1,066 | -27% |
R&D Budget: | $3,358 | 6% |
Top Selling Drugs
Drug | Indication | 2013 Sales | (+/- %) |
Candesartan | hypertension | $1,507 | -14% |
Leuprorelin | prostatic cancer | $1,206 | 8% |
Pioglitazone | ype 2 diabetes | $1,196 | 37% |
Lansoproazole | peptic ulcers | $1,148 | 8% |
Pantoprazole | GERD | $1,050 | 25% |
Velcade | multiple myeloma | $924 | 73% |
Colcrys | gout | $506 | 18% |
Dexilant | GERD | $486 | 4% |
Nesina | type 2 diabetes | $389 | 5% |
Uloric | high uric acid | $263 | 92% |
Amitzia | IBS | $253 | 3% |
Calcium | hypertension | $185 | 15% |
Adcetris | Hodgkin lymphoma | $136 | 5% |
In late June, Takeda Pharmaceuticals held its 13th ordinary general meeting of shareholders, and there was a bit of tension there. The company appointed Christophe Weber, a veteran of GSK who is French, as the company’s president and COO, with Yasuchika Hasegawa remaining Chairman and CEO.
As news magazines reported,this was the first time a foreigner had been appointed as a senior executive at the venerable Japanese company. Although the company’s shareholders reportedly voted for Mr. Weber by a large margin, one group of shareholders questioned his appointment and Takeda’s globalization strategy, which has included acquisitions of drugmakers like Nycomed of Switzerland and Millennium Pharmaceuticals of the United States.
In addition, media reported that over 100 members of the Takeda family and former executives signed a letter of protest, reportedly based on fear that he might approve Takeda’s sale to a foreign company.
Chairman reaffirms the need for growth and diversity
The company’s chairman Hasegawa addressed criticism of the Millenium and Nycomed acquisitions at the meeting, before the live Q&A.
“Takeda’s presently decreasing profit is not the effect of these acquisitions, but rather due to structural changes that have progressed rapidly, particularly in Japan and the U.S., such as decreasing sales due to generic drug penetration. Following the patent expiry of Takeda’s four blockbusters that had previously driven our performance, as well as decreasing profitability due to the decreasing ratio of inhouse products.
Post-Blockbuster Era Challenges
I’d like to illustrate this through the example of Actos, one of the largest factors in our decreasing profits. Global sales of Actos decreased from 387.9 billion yen in fiscal year 2010 to 36.6 billion yen in 2013 following expiration of its patent protection.The acquisitions were countermeasures designed to assure and recover our growth. With Millennium, Takeda gained access to a strong oncology franchise and strengthened our presence in the U.S., the largest market in the world.
With the Nycomed acquisition, Takeda gained attractive positioning in locations where we were not previously, thus expanding our global footprint to areas from which we can now launch products that we developed ourselves.
Millennium is an important subsidiary in charge of R&D in oncology. Sales in the U.S. for the multiple myeloma drug Velcade were 95 billion yen in 2013, 30% up from the previous year, and we recovered almost 35 billion yen in royalties. Entyvio was approved in the U.S. and Europe and has been launched and has the potential to generate blockbuster sales. MLN9708 is in the final stages of development as Velcade’s successor in our multiple mueloma franchise, and is now in Phase III development…”
Takeda’s leadership seems committed to looking within and without its boundaries to strengthen its innovation.